Format

Send to

Choose Destination
Ann Oncol. 2013 Dec;24(12):3017-23. doi: 10.1093/annonc/mdt390. Epub 2013 Oct 10.

Discordance in ERα, PR and HER2 receptor status across different distant breast cancer metastases within the same patient.

Author information

1
Department of Pathology.

Abstract

BACKGROUND:

We studied discordance in estrogen receptor alpha (ERα), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status between multiple distant metastases from the same breast cancer patient.

MATERIAL AND METHODS:

Multiple distant metastases from 55 female patients were stained for ERα, PR and HER2 by immunohistochemistry and in situ hybridization for confirmation of the HER2 status.

RESULTS:

Different metastatic sites within the same patient showed discordance in ERα receptor status in 7.3% or 10.9% of patients (using a 10% or 1% threshold for positivity, respectively). For PR, 29.1% or 30.9% of patients showed discordance. Taking ERα and PR together, 36.4% of cases (both thresholds) showed discrepancy between metastases. In 10.9% (10% threshold) or 14.5% of patients (1% threshold), such discordance could have clinical consequences with regard to hormonal treatment. For HER2, there was 3.6% discordance on the immunohistochemical level but 0% on the gene level.

CONCLUSION:

In a significant proportion of metastatic breast cancer patients, discordance in ERα and PR receptor status between different metastatic sites was observed. This implies that multiple metastases may need to be biopsied to optimally reassess receptors.

KEYWORDS:

ERα; HER2; PR; breast cancer; immunohistochemistry; multiple metastases

PMID:
24114857
DOI:
10.1093/annonc/mdt390
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center